Oppenheimer on Lexeo Therapeutics (LXEO): 'We regard the selloff as having made the shares more attractive'
Tweet Send to a Friend
(Updated - January 13, 2026 6:23 AM EST)
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $20.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $20.00 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
